FIMASARTAN

/static/temp/default.svg

Search structure


Synonyms	Fimasartan
Status
Molecule Category	UNKNOWN
ATC	C09CA10
UNII	P58222188P
EPA CompTox	DTXSID80179460


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	AMEROGPZOLAFBN-UHFFFAOYSA-N
Smiles	CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
InChI	InChI=1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C27H31N7OS
Molecular Weight	501.66
AlogP	4.22
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	9.0
Polar Surface Area	92.59
Molecular species	ACID
Aromatic Rings	4.0
Heavy Atoms	36.0

Bioactivity

Mechanism of Action	Action	Reference
Type-1 angiotensin II receptor antagonist	ANTAGONIST	PubMed PubMed


Protein: Type-1 angiotensin II receptor Description: Type-1 angiotensin II receptor Organism : Homo sapiens P30556 ENSG00000144891

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Short peptide receptor (family A GPCR) Angiotensin receptor	-	0	-	-	-

Assay Description	Organism	Bioactivity	Reference
Antagonist activity at angiotensin 2 receptor type 1 in New Zealand White rabbit descending thoracic aorta rings assessed as inhibition of angiotensin 2-induced contraction preincubated for 30 mins prior angiotensin 2 challenge	Oryctolagus cuniculus	0.42 nM
Displacement of [125I]angiotensin 2 from angiotensin 2 receptor type 1 in Sprague-Dawley rat adrenal cortex membranes after 60 mins by gamma counting	Rattus norvegicus	0.13 nM
Antagonist activity at type-1 angiotensin 2 receptor (unknown origin) by calcium mobilizing assay	Homo sapiens	4.5 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	5.65 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	-18.62 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.07 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.07 %

Cross References

Resources	Reference
ChEBI	136044
ChEMBL	CHEMBL1951143
DrugBank	DB09279
DrugCentral	4906
FDA SRS	P58222188P
PubChem	9870652
SureChEMBL	SCHEMBL20126833
ZINC	ZINC000003842872

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).